Analyst firms · Citigroup · GH

Citigroup GH price target and rating history

Guardant Health Inc. (GH) · Health Care

Citigroup rates Guardant Health Inc. (GH) Buy with a $40 price target, as of its latest action on May 26, 2023. It has published 3 rating actions on GH since February 2022, including 1 upgrade and 1 downgrade. Across 11 firms with a GH price target in the last 12 months, the median target is $165.

Current rating

Buy

Price target

$40

Median target, all firms

$165

Actions on GH

3

Citigroup price target on GH

Every Citigroup rating on GH

• May 26, 2023
  UpgradeCitigroup upgrades to Buy from Neutral, price target $28 to $40
• Mar 9, 2023
  DowngradeCitigroup downgrades to Neutral from Buy, price target $60 to $33
• Feb 24, 2022
  ReiterateCitigroup cuts its price target to $120 from $180, keeps Buy

How other firms rate GH

Each firm's latest rating and stated target in the last 12 months.

Questions about Citigroup and GH

What is Citigroup's price target for GH?

Citigroup's latest stated price target for Guardant Health Inc. (GH) is $40, from its action on May 26, 2023.

What is Citigroup's rating on GH?

Citigroup rates GH Buy, a bullish rating, as of May 26, 2023.

When did Citigroup last change its view on GH?

On May 26, 2023, Citigroup upgrades to Buy from Neutral, price target $28 to $40.

How does Citigroup's GH target compare with other analysts?

Across 11 firms with a GH price target in the last 12 months, the median target is $165.

More GH rating histories

• Wolfe Research3
• Morgan Stanley3
• Piper Sandler3

All Citigroup ratingsGH news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.